2026 Interim report
Filed with HKEX · Stock code 2005 · · 73 pages · English
Summary by 6ix AI
The report highlights a revenue increase compared to the same period last year, alongside a rise in net profit and a proposed interim dividend. The company discusses its strategic focus on innovation and market expansion in the pharmaceutical sector, emphasizing product development and market access initiatives. Additionally, the report outlines the Group's efforts in research and development, infrastructure projects, and future growth prospects.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from SSY
- Voluntary announcement - update on product development
- (1) Continuing connected transactions - Master Sale and purchase agreement and (2) notice of extraordinary general meeting
- SSY Group: Unaudited operating results for the three months ended 31 March 2021
- SSY Group: Proposals for general mandates to issue and repurchase shares, re-election of retiring directors, declaration of final dividend and notice of annual general meeting
- Continuing connected transactions - master sale and purchase agreement
Later from SSY
- Notification Letter and Reply Form to Registered Shareholders - Notice of Publication of 2026 Interim Report
- Notification Letter and Reply Form to Non-registered Shareholders - Notice of Publication of 2026 Interim Report
- Next Day Disclosure Return
- Change of executive directors
- List of Directors and their Role and Function
Follow SSY into a list and get an email when it puts out news.
Follow SSY